Skip to content

Solid Biosciences Inc. SLDB Finance Lease Liabilities

Finance Lease Liabilities at other companies

Insmed logo
InsmedINSM
$19.82M-14.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$3M-80.7%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+135%
Enterprise value$634.23M+223%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: Solid Biosciences Inc.’s 10-K, filed March 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s finance lease liabilities?
Solid Biosciences Inc. (SLDB) reported finance lease liabilities of $0 in Q4 2024.
How has Solid Biosciences Inc.'s finance lease liabilities changed year-over-year?
Solid Biosciences Inc.'s finance lease liabilities decreased by 100.0% year-over-year, from $1.23M to $0.
What is the long-term trend for Solid Biosciences Inc.'s finance lease liabilities?
Over 4 years (2020 to 2024), Solid Biosciences Inc.'s finance lease liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $525K to $0.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.